Table 3.
Incidence rates for 2006–2010 and fixed-interval trends for 2001–2010 for the top 15 cancers by sex, race, and ethnicity, for areas in the United States with high-quality incidence dataa
| All races/ethnicities |
Whiteb | Blackb | APIb | AI/AN (CHSDA)b |
Hispanicb | Non-Hispanicb | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex/cancer site or type |
R a n k |
Ratec | 2001– 2010 AAPC d |
2006– 2010 AAPC d |
R a n k |
Ratec | 2001– 2010 AAPC d |
R a n k |
Ratec | 2001– 2010 AAP Cd |
R a n k |
Ratec | 2001– 2010 AAPC d |
R a n k |
Ratec | 2001 – 2010 AA PCd |
R a n k |
Rate c |
2001– 2010 AAPC d |
R a n k |
Ratec | 2001– 2010 AAPC d |
| All sitese | ||||||||||||||||||||||
| Both sexes | 462.6 | −1.1 f | −1.6 f | 463.2 | −1.2 f | 471.7 | −0.9 f | 293.5 | −0.8 f | 393.8 | −0.5 | 361.7 | −1.4 f | 473.4 | −1.0 f | |||||||
| Males | 532.7 | −1.6 f | −2.5 f | 526.3 | −1.7 f | 593.9 | −1.8 f | 319.3 | −1.7 f | 435.1 | −0.8 | 419.2 | −2.0 f | 544.4 | −1.6 f | |||||||
| Females | 412.6 | −0.3 f | −0.3 f | 418.6 | −0.4 f | 390.6 | −0.1 | 278.4 | 0.0 | 367.2 | −0.2 | 325.1 | −0.8 f | 422.3 | −0.2 | |||||||
| Children (ages 0-14) |
15.9 | 0.5 f | 0.5 f | 16.5 | 0.4 | 12.2 | 1.1 f | 12.5 | −0.2 | 11.1 | −2.7 | 15.7 | 0.2 | 15.9 | 0.6 f | |||||||
| Children (ages 0-19) |
17.2 | 0.3 | 0.3 | 18.1 | 0.3 | 12.8 | 1.0 f | 13.2 | 0.2 | 12.3 | −2.5 f | 16.7 | 0.2 | 17.4 | 0.4 f | |||||||
| Malesg | ||||||||||||||||||||||
| Prostate | 1 | 146.6 | −3.6 f | −5.2 f | 1 | 136.6 | −4.0 f | 1 | 220.0 | −2.6 f | 1 | 75.0 | −3.9 f | 1 | 104.1 | −2.3 f | 1 | 124.2 | −3.1 f | 1 | 148.9 | −3.5 f |
| Lung and bronchus |
2 | 80.0 | −2.4 f | −3.2 f | 2 | 79.6 | −2.3 f | 2 | 94.7 | −2.7 f | 2 | 48.8 | −1.5 f | 2 | 70.2 | −1.4 | 3 | 45.9 | −2.7 f | 2 | 83.1 | −2.2 f |
| Colon and rectum |
3 | 51.7 | −3.8 f | −4.5 f | 3 | 50.5 | −4.0 f | 3 | 62.5 | −2.0 f | 3 | 40.8 | −2.8 f | 3 | 51.7 | −1.4 | 2 | 47.3 | −2.9 f | 3 | 52.2 | −3.8 f |
| Urinary bladder |
4 | 36.9 | −0.9 f | −1.7 f | 4 | 39.0 | −1.0 f | 5 | 19.0 | 0.0 | 6 | 15.5 | −0.7 | 5 | 18.3 | 0.1 | 4 | 20.8 | −1.7 f | 4 | 38.2 | −0.8 f |
| Melanoma of the skin |
5 | 24.7 | 1.6 f | 1.6 f | 5 | 27.5 | 1.6 f | 25 | 1.1 | −0.4 | 20 | 1.5 | −1.8 | 13 | 7.1 | 1.0 | 17 | 4.7 | −1.7 | 5 | 26.9 | 1.8 f |
| Non- Hodgkin lymphoma |
6 | 23.3 | −0.1 | −0.8 | 6 | 23.9 | −0.2 | 6 | 16.8 | −0.2 | 7 | 15.0 | −0.4 | 7 | 16.5 | −0.7 | 6 | 20.1 | −0.3 | 6 | 23.6 | 0.0 |
| Kidney and renal pelvis |
7 | 21.4 | 1.3 f | −0.2 | 7 | 21.5 | 1.4 f | 4 | 23.0 | 2.1 f | 9 | 10.6 | 3.1 f | 4 | 30.6 | 5.1 f | 5 | 20.5 | 1.2 f | 7 | 21.5 | 1.5 f |
| Oral cavity and pharynx |
8 | 16.5 | 0.2 | 0.2 | 9 | 16.8 | 0.5 f | 9 | 15.2 | −3.0 f | 8 | 10.7 | 0.1 | 8 | 14.0 | 2.1 | 11 | 10.6 | −1.4 f | 8 | 17.3 | 0.4 |
| Leukemia | 9 | 16.4 | −0.8 f | −0.8 f | 8 | 16.9 | −0.9 f | 1 2 |
12.4 | −0.8 f | 11 | 8.9 | −0.7 | 10 | 11.7 | −1.7 | 9 | 12.8 | −0.7 | 9 | 16.6 | −0.8 f |
| Pancreas | 10 | 13.7 | 0.7 f | 0.7 f | 10 | 13.6 | 0.7 f | 7 | 16.7 | 0.8 f | 10 | 9.7 | 0.1 | 11 | 10.8 | 0.4 | 10 | 12.0 | 0.2 | 10 | 13.9 | 0.8 f |
| Liver and intrahepatic bile duct |
11 | 10.8 | 3.9 f | 3.9 f | 11 | 9.6 | 4.1 f | 10 | 14.9 | 4.3 f | 4 | 21.3 | −0.9 | 6 | 17.8 | 4.4 f | 7 | 18.8 | 3.0 f | 11 | 10.1 | 3.8 f |
| Stomach | 12 | 9.4 | −1.7 f | −1.7 f | 13 | 8.4 | −1.8 f | 8 | 15.7 | −1.8 f | 5 | 15.6 | −3.3 f | 9 | 13.1 | −4.8 f | 8 | 13.9 | −2.0 f | 12 | 9.0 | −1.8 f |
| Esophagus | 13 | 8.5 | −1.0 f | −2.3 f | 12 | 8.6 | −0.5 | 14 | 8.7 | −5.0 f | 15 | 3.9 | −0.9 | 12 | 7.2 | −2.2 | 15 | 5.4 | −1.6 f | 13 | 8.7 | −0.8 |
| Brain and other nervous system |
14 | 7.8 | −0.6 f | −1.2 f | 14 | 8.4 | −0.4 f | 15 | 4.6 | −0.5 | 13 | 4.3 | −0.9 | 16 | 5.3 | −0.9 | 13 | 6.0 | −1.2 f | 14 | 8.1 | −0.3 |
| Myeloma | 15 | 7.4 | 0.1 | 0.1 | 15 | 6.8 | −0.2 | 11 | 13.9 | 0.2 | 14 | 4.3 | 1.9 f | 15 | 6.0 | −4.9 f | 12 | 7.0 | −0.5 | 15 | 7.4 | 0.1 |
| Larynx | 16 | 6.6 | −2.4 f | −2.4 f | 17 | 6.4 | −2.5 f | 13 | 9.9 | −3.3 f | 18 | 2.3 | −1.9 | 14 | 6.2 | −0.3 | 14 | 5.6 | −3.0 f | 16 | 6.8 | −2.3 f |
| Thyroid | 17 | 6.3 | 6.3 f | 6.3 f | 16 | 6.7 | 6.4 f | 18 | 3.3 | 5.4 f | 12 | 5.5 | 5.2 f | 20 | 3.3 | 3.8 | 16 | 4.7 | 4.8 f | 17 | 6.6 | 6.5 f |
| Femalesg | ||||||||||||||||||||||
| Breast | 1 | 122.2 | −1.0 | 0.0 | 1 | 123.5 | −1.1 | 1 | 118.4 | 0.5 f | 1 | 84.7 | 0.4 | 1 | 90.3 | −0.5 | 1 | 91.1 | −0.6 | 1 | 125.6 | −0.9 |
| Lung and bronchus |
2 | 55.1 | −0.7 f | −1.8 f | 2 | 56.8 | −0.6 f | 2 | 50.4 | −0.1 | 3 | 28.0 | 0.0 | 2 | 52.1 | −0.3 | 3 | 26.6 | −1.0 f | 2 | 57.7 | −0.5 f |
| Colon and rectum |
3 | 39.1 | −3.2 f | −4.0 f | 3 | 38.0 | −3.3 f | 3 | 46.7 | −2.9 f | 2 | 31.0 | −2.2 f | 3 | 42.7 | −1.3 f | 2 | 32.6 | −2.8 f | 3 | 39.7 | −3.1 f |
| Corpus and uterus, NOS |
4 | 24.6 | 0.4 | 1.1 f | 4 | 25.0 | 0.3 | 4 | 23.0 | 2.0 f | 5 | 16.9 | 2.3 f | 4 | 22.4 | 1.8 | 4 | 20.1 | 1.0 f | 4 | 25.0 | 0.4 |
| Thyroid | 5 | 18.5 | 6.4 f | 5.1 f | 5 | 19.6 | 6.4 f | 8 | 11.2 | 6.1 f | 4 | 18.5 | 6.0 f | 7 | 11.6 | 3.3 f | 5 | 17.4 | 6.0 f | 5 | 18.9 | 6.4 f |
| Non- Hodgkin lymphoma |
6 | 16.3 | −0.2 | −0.9 f | 7 | 16.8 | −0.3 | 7 | 11.7 | 0.1 | 6 | 10.4 | −0.7 | 6 | 14.2 | −1.0 | 6 | 15.2 | −0.2 | 7 | 16.4 | −0.2 |
| Melanoma of the skin |
7 | 15.6 | 1.4 f | 1.4 f | 6 | 18.0 | 1.6 f | 27 | 1.0 | −1.0 | 22 | 1.1 | −2.2 | 14 | 5.5 | 0.1 | 18 | 4.0 | −1.5 | 6 | 17.3 | 1.8 f |
| Ovary | 8 | 12.3 | −2.2 f | −2.9 f | 8 | 12.8 | −2.3 f | 11 | 9.4 | −1.5 f | 8 | 9.0 | −1.6 f | 8 | 11.6 | −2.0 | 9 | 10.9 | −2.1 f | 8 | 12.4 | −2.2 f |
| Kidney and renal pelvis |
9 | 11.2 | 1.6 f | −0.1 | 9 | 11.3 | 1.9 f | 6 | 12.2 | 3.0 f | 13 | 5.1 | 2.0 | 5 | 17.5 | 2.1 | 7 | 11.5 | 1.5 f | 9 | 11.2 | 1.7 f |
| Pancreas | 10 | 10.7 | 0.7 f | 0.1 | 10 | 10.4 | 0.7 f | 5 | 13.9 | 0.4 | 9 | 8.3 | 0.8 | 9 | 10.0 | −0.5 | 10 | 10.2 | 0.2 | 10 | 10.8 | 0.8 f |
| Leukemia | 11 | 10.0 | −0.5 f | −0.5 f | 11 | 10.3 | −0.5 f | 13 | 7.8 | −0.9 f | 12 | 6.0 | 0.7 | 12 | 8.0 | −0.1 | 11 | 8.8 | −0.5 | 11 | 10.0 | −0.5 f |
| Urinary bladder |
12 | 9.1 | −1.2 f | −1.2 f | 12 | 9.6 | −1.3 f | 14 | 6.6 | −0.9 | 15 | 3.8 | −1.0 | 17 | 4.7 | −1.6 | 14 | 5.2 | −2.4 f | 12 | 9.5 | −0.9 |
| Cervix uteri | 13 | 8.0 | −1.9 f | −1.2 f | 13 | 7.7 | −1.5 f | 9 | 10.3 | −2.9 f | 11 | 6.7 | −3.5 f | 10 | 9.7 | 0.4 | 8 | 10.9 | −4.2 f | 13 | 7.6 | −1.6 f |
| Oral cavity and pharynx |
14 | 6.2 | 0.0 | 0.0 | 14 | 6.3 | 0.3 | 15 | 5.2 | −1.4 f | 14 | 4.8 | −1.7 f | 15 | 5.0 | −4.1 | 17 | 4.2 | 0.2 | 14 | 6.5 | 0.1 |
| Brain and other nervous system |
15 | 5.7 | −0.5 | −1.6 f | 15 | 6.1 | −0.5 | 17 | 3.6 | −0.4 | 16 | 3.0 | −0.8 | 18 | 4.2 | −0.7 | 16 | 4.7 | −1.2 f | 15 | 5.8 | −0.3 |
| Myeloma | 16 | 4.8 | 0.0 | 0.0 | 16 | 4.2 | −0.4 f | 10 | 10.2 | 0.5 | 17 | 2.9 | 0.1 | 16 | 4.9 | −4.2 | 15 | 4.9 | −1.5 f | 16 | 4.8 | 0.1 |
| Stomach | 17 | 4.7 | −1.1 f | −1.1 f | 17 | 4.0 | −1.4 f | 12 | 8.1 | −1.5 f | 7 | 9.0 | −2.8 f | 13 | 6.9 | −2.6 | 12 | 8.2 | −2.1 f | 17 | 4.3 | −1.3 f |
| Liver and intrahepatic bile duct |
18 | 3.7 | 3.4 f | 3.4 f | 18 | 3.3 | 3.5 f | 16 | 4.4 | 3.5 f | 10 | 8.0 | −0.6 | 11 | 8.0 | 2.5 | 13 | 6.9 | 2.1 f | 18 | 3.4 | 3.3 f |
Abbreviations: API, Asian/Pacific Islander; AI/AN, American Indian/Alaska Native; IHS, Indian Health Service; CHSDA, IHS Contract Health Services Delivery Area; AAPC, average annual percent change; NOS, not otherwise specified; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results; NAACCR, North American Association of Central Cancer Registries; APC, annual percent change.
Source: NPCR and SEER areas reported by NAACCR as meeting high-quality incidence data standards for the specified time periods.
White, black, API, and AI/AN (CHSDA 2012 counties) include Hispanic and non-Hispanic; the race and ethnicity categories are not mutually exclusive. AI/AN (CHSDA 2012) statistics exclude data from Kansas.
Rates are per 100,000 persons and were age standardized to the 2000 US standard population (19 age groups: ages <1 year, 1-4 years, 5-9 years, …, 80-84 years, ≥85 years; Census publication p25-1130; US Bureau of the Census, Current Population Reports, p25-1130. Washington, DC: US Government Printing Office, 2000)
AAPC is a weighted average of the APCs that is calculated by joinpoint regression over the time period 2001–2010 unless otherwise noted. Joinpoint analyses with up to 2 joinpoints yielding up to 3 trend segments were based on rates per 100,000 persons and were age-adjusted to the 2000 US standard population (19 age groups; Census publication p25-1130). For joinpoint analysis, the Joinpoint Regression Program was used (version 4.0.3, April 2013; Surveillance Research Program, National Cancer Institute, Bethesda, Md).
For all sites, myelodysplastic syndromes are included for the rate calculations but not for the APC calculations; they are excluded from cancer-specific analysis. Ovary excludes borderline tumors.
The AAPC is statistically significantly different from zero (2-sided Z test; P < .05).
Cancers are listed in descending rank order according to sex-specific, age-adjusted rates for 2006 through 2010 for all racial and ethnic groups combined. More than 15 cancers may appear under men and women to include the top 15 cancers in each racial and ethnic group.
2006-2010 rates for all races/ethnicities, white, black, AI/AN, API, Hispanic, and non-Hispanic (46 states): Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Washington, West Virginia, Wisconsin, Wyoming.
2001-2010 AAPCs for all races/ethnicities, white, black, AI/AN, API, Hispanic, and non-Hispanic (42 states): Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Texas, Utah, Vermont, Washington, West Virginia, Wisconsin, Wyoming.